B. Furmanski

Plastic Antibodies: Molecular Recognition with Imprinted Polymers. An Introductory Polymer Chemistry Laboratory Investigation

K. Shimizu, Gregory T. Rushton, B. Furmanski, 2005 .

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.

P. Keegan, B. Booth, B. Furmanski, 2019, Annals of Oncology.

Biological activities of fusarochromanone: a potent anti-cancer agent

J. Clifford, Yang Wu, Shile Huang, 2014, BMC Research Notes.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

S. Shurtleff, D. Campana, C. Pui, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.

P. Keegan, B. Booth, B. Furmanski, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Hybrid assays: the next big thing?

Brian P Booth, Brian Furmanski, B. Booth, 2018, Bioanalysis.

Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib

S. Baker, A. Gibson, R. Williams, 2013, Clinical Cancer Research.

Differential Uptake and Selective Permeability of Fusarochromanone (FC101), a Novel Membrane Permeable Anticancer Naturally Fluorescent Compound in Tumor and Normal Cells

D. Dréau, R. Wuthier, J. Fuseler, 2009, Microscopy and Microanalysis.

Biological activities of fusarochromanone: a potent anti-cancer agent

J. Clifford, Yang Wu, Shile Huang, 2014, BMC Research Notes.

Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.

S. Shurtleff, D. Campana, C. Pui, 2010 .